Showing 4941-4950 of 7167 results for "".
- Chicken or the Egg? Unravelling the Role of Demodex in Rosaceahttps://practicaldermatology.com/news/chicken-or-the-egg-unravelling-the-role-of-demodex-in-rosacea/2461346/Researchers have long observed that microscopic mites that live as scavengers on normal human skin tend to occur in greater numbers on the faces of rosacea patients. It was unknown, however, whether the higher density of these Demodex, was a cause or an effect of this widespread disease.
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- Dermalogica Gives Back: Brand Launches Grant Program to Empower the Next Generation of Industry Proshttps://practicaldermatology.com/news/dermalogica-gives-back-brand-launches-grant-program-to-empower-the-next-generation-of-industry-pros/2461337/Dermalogica is offering a new grant program for non-profit organizations that help give greater access to skillset training in the United States. The grant program is now accepting applications and supports education, mentorship, and skills training for non-profits training therap
- EADV 2022 News: Otezla Works Well in Kids with PsO, Adults with Genital PsOhttps://practicaldermatology.com/news/eadv-2022-news-otezla-works-well-in-kids-with-pso-adults-with-genital-pso/2461332/Otezla (apremilast) performs well in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy. 
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Paul Navarre Joins LEO Pharma’s Board of Directorshttps://practicaldermatology.com/news/paul-navarre-joins-leo-pharmas-board-of-directors/2461324/Paul Navarre is the newest member of LEO Pharma’s Board of Directors. Mr. Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- UK Study: Psoriasis Diagnoses in Primary Care Delayed by Up to 5 Yearshttps://practicaldermatology.com/news/uk-study-psoriasis-diagnoses-in-primary-care-delayed-by-up-to-5-years/2461322/Psoriasis may be underdiagnosed in UK primary care settings, according to research out of the University of Manchester in The British Journal of General Practice. Patients who are later diagnosed with psoriasis are twice as likely to be prescribed steroid or antifungal creams t
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous BCChttps://practicaldermatology.com/news/sirnaomics-achieves-100-complete-response-in-phase-ii-clinical-trial-of-stp705-for-treatment-of-cutaneous-bcc/2461319/Patients receiving the 180μg dose level in the Phase II clinical trial of STP705 for the treatment of cutaneous basal cell carcinoma (BCC) achieved a 100% complete response, with no safety signals, Sirnaomics reports. STP705 is a siRNA (small inte